Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs.

Maalej N, Osman HE, Shanmuganayagam D, Shebuski RJ, Folts JD.

J Cardiovasc Pharmacol. 2005 May;45(5):389-95.

PMID:
15821433
2.

Development and applications of animal models of thrombosis.

Shebuski RJ, Bush LR, Gagnon A, Chi L, Leadley RJ Jr.

Methods Mol Med. 2004;93:175-219. Review. No abstract available.

PMID:
14733334
3.
4.

Role of inflammatory mediators in thrombogenesis.

Shebuski RJ, Kilgore KS.

J Pharmacol Exp Ther. 2002 Mar;300(3):729-35. Review.

PMID:
11861775
5.

Meeting report of the ASPET colloquium: functional genomics.

Porcari AR, Shebuski RJ.

J Pharmacol Exp Ther. 2000 Dec;295(3):1291-5. No abstract available.

PMID:
11082467
6.

Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice.

Kumar A, Hoover JL, Simmons CA, Lindner V, Shebuski RJ.

Circulation. 1997 Dec 16;96(12):4333-42.

PMID:
9416901
7.

Temporal expression of c-fos mRNA following balloon injury in the rat common carotid artery.

Mills CJ, Northrup JL, Hullinger TG, Simmons CA, Shebuski RJ, Jones DA.

Cardiovasc Res. 1996 Nov;32(5):954-61.

PMID:
8944827
8.

Inhibition of thrombus formation by endothelin-1 in canine models of arterial thrombosis.

Leadley RJ Jr, Humphrey WR, Erickson LA, Shebuski RJ.

Thromb Haemost. 1995 Dec;74(6):1583-90.

PMID:
8772241
9.

Pretreatment with a blocking monoclonal antibody to P-selectin accelerates pharmacological thrombolysis in a primate model of arterial thrombosis.

Toombs CF, DeGraaf GL, Martin JP, Geng JG, Anderson DC, Shebuski RJ.

J Pharmacol Exp Ther. 1995 Nov;275(2):941-9.

PMID:
7473186
10.

Protection of ischemic/reperfused canine myocardium by CL18/6, a monoclonal antibody to adhesion molecule ICAM-1.

Hartman JC, Anderson DC, Wiltse AL, Lane CL, Rosenbloom CL, Manning AM, Humphrey WR, Wall TM, Shebuski RJ.

Cardiovasc Res. 1995 Jul;30(1):47-54.

PMID:
7553723
11.

The role of adhesion molecules in cardiovascular pharmacology: meeting review.

Virkhaus R, Lucchesi BR, Simpson PJ, Shebuski RJ.

J Pharmacol Exp Ther. 1995 May;273(2):569-75. No abstract available.

PMID:
7752057
12.

NF-kappa B is activated during acute inflammation in vivo in association with elevated endothelial cell adhesion molecule gene expression and leukocyte recruitment.

Manning AM, Bell FP, Rosenbloom CL, Chosay JG, Simmons CA, Northrup JL, Shebuski RJ, Dunn CJ, Anderson DC.

J Inflamm. 1995;45(4):283-96.

PMID:
8867672
13.

Inhibition of nitric oxide synthase prevents myocardial protection by ramiprilat.

Hartman JC, Kurc GM, Hullinger TG, Wall TM, Sheehy RM, Shebuski RJ.

J Pharmacol Exp Ther. 1994 Sep;270(3):1071-6.

PMID:
7523655
14.
15.

Comparative effects of the potassium channel openers cromakalim and pinacidil and the cromakalim analog U-89232 on isolated vascular and cardiac tissue.

Norman NR, Toombs CF, Khan SA, Buchanan LV, Cimini MG, Gibson JK, Meisheri KD, Shebuski RJ.

Pharmacology. 1994 Aug;49(2):86-95.

PMID:
7972325
16.

Induction of neointimal hyperplasia by coronary angioplasty balloon overinflation: comparison of feeder pigs to Yucatan minipigs.

Humphrey WR, Simmons CA, Toombs CF, Shebuski RJ.

Am Heart J. 1994 Jan;127(1):20-31.

PMID:
8273740
18.

Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.

Hartman JC, Wall TM, Hullinger TG, Shebuski RJ.

J Cardiovasc Pharmacol. 1993 Jun;21(6):996-1003.

PMID:
7687728
19.

Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.

Hartman JC, Hullinger TG, Wall TM, Shebuski RJ.

Eur J Pharmacol. 1993 Apr 6;234(2-3):229-36.

PMID:
8482328
20.

Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide.

Toombs CF, Moore TL, Shebuski RJ.

Cardiovasc Res. 1993 Apr;27(4):617-22.

PMID:
8324795
21.

Interruption of thrombosis and hemostasis by anti-platelet agents.

Shebuski RJ.

Toxicol Pathol. 1993;21(2):180-9.

PMID:
8210940
22.

The snake venom peptide sarafotoxin S6b inhibits repetitive platelet thrombus formation in the stenosed canine coronary artery.

Leadley RJ Jr, Lee P, Erickson LA, Shebuski RJ.

J Cardiovasc Pharmacol. 1993;22 Suppl 8:S199-203.

PMID:
7509944
23.

Principles underlying the use of conjunctive agents with plasminogen activators.

Shebuski RJ.

Ann N Y Acad Sci. 1992 Dec 4;667:382-94. Review.

PMID:
1309058
24.

Limitation of myocardial injury with the potassium channel opener cromakalim and the nonvasoactive analog U-89,232: vascular vs. cardiac actions in vitro and in vivo.

Toombs CF, Norman NR, Groppi VE, Lee KS, Gadwood RC, Shebuski RJ.

J Pharmacol Exp Ther. 1992 Dec;263(3):1261-8.

PMID:
1469632
25.

Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.

Reilly CF, Fujita T, Hutzelmann JE, Mayer EJ, Shebuski RJ.

Circulation. 1991 Jul;84(1):287-92.

PMID:
1905594
26.
28.
29.

The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit.

Mayer EJ, Fujita T, Gardell SJ, Shebuski RJ, Reilly CF.

Blood. 1990 Oct 15;76(8):1514-20.

30.

In vivo models of arterial thrombosis and thrombolysis.

Bush LR, Shebuski RJ.

FASEB J. 1990 Oct;4(13):3087-98. Review.

PMID:
2210155
32.
34.

Combination of the thromboxane receptor antagonist, sulotroban (BM 13.177; SK&F 95587), with streptokinase: demonstration of thrombolytic synergy.

Kopia GA, Kopaciewicz LJ, Ohlstein EH, Horohonich S, Storer BL, Shebuski RJ.

J Pharmacol Exp Ther. 1989 Sep;250(3):887-95.

PMID:
2528630
35.

Demonstration of Ac-Arg-Gly-Asp-Ser-NH2 as an antiaggregatory agent in the dog by intracoronary administration.

Shebuski RJ, Berry DE, Bennett DB, Romoff T, Storer BL, Ali F, Samanen J.

Thromb Haemost. 1989 Apr 25;61(2):183-8.

PMID:
2749593
36.

Effect of dopamine, ibopamine, and epinine on alpha- and beta-adrenoceptors in canine pulmonary circulation.

Shebuski RJ, Smith JM Jr, Ruffolo R Jr.

Fundam Clin Pharmacol. 1989;3(3):211-21.

PMID:
2548941
37.

Localization and characterization of alpha-2 adrenoceptors in the isolated canine pulmonary vein.

Ohlstein EH, Horohonich S, Shebuski RJ, Ruffolo RR Jr.

J Pharmacol Exp Ther. 1989 Jan;248(1):233-9.

PMID:
2536428
38.
40.

DHFR coamplification of t-PA in DHFR+ bovine endothelial cells: in vitro characterization of the purified serine protease.

Connors RW, Sweet RW, Noveral JP, Pfarr DS, Trill JJ, Shebuski RJ, Berkowitz BA, Williams D, Franklin S, Reff ME.

DNA. 1988 Nov;7(9):651-61.

PMID:
3147883
42.
43.

Inhibition of plasma cholinesterase prevents the dopamine DA-1 receptor mediated renal vasodilation produced by ibopamine.

Nichols AJ, Shebuski RJ, Ruffolo RR Jr.

Eur J Pharmacol. 1987 Sep 23;141(3):515-8.

PMID:
3666046
44.
45.

Enhanced pulmonary alpha-2 adrenoceptor responsiveness under conditions of elevated pulmonary vascular tone.

Shebuski RJ, Ohlstein EH, Smith JM Jr, Ruffolo RR Jr.

J Pharmacol Exp Ther. 1987 Jul;242(1):158-65.

PMID:
3039109
46.

Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit.

Ohlstein EH, Storer B, Fujita T, Shebuski RJ.

Thromb Res. 1987 May 15;46(4):575-85.

PMID:
3112993
47.

Comparison of the alpha adrenoceptor activity of dopamine, ibopamine and epinine in the pulmonary circulation of the dog.

Shebuski RJ, Fujita T, Smith JM Jr, Ruffolo RR Jr.

J Pharmacol Exp Ther. 1987 Apr;241(1):6-12.

PMID:
3033210
49.
50.

Beta 1-adrenoceptor antagonism by urapidil prior to and after the alpha 2-antagonist rauwolscine in anesthetized dogs.

Rassier ME, Shebuski RJ, Zimmerman BG.

Eur J Pharmacol. 1986 Mar 11;122(1):37-43.

PMID:
3007177

Supplemental Content

Loading ...
Support Center